Prespecified event-driven analysis of overall survival in the OlympiA phase III trial of adjuvant olaparib in germline BRCA1/2 mutation associated breast cancer. ESMO Virtual Plenary Abstract VP1–2022 Presented March 16, 2022 - Tutt, A; Garber, JE; Gelber, RD (2022)
et al.